Physician profile
Nitin S Damle
NPI 1457399388
$4,090.28
in general payments reported to CMS, 2019-2025
26 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $35.19 · 2021: $23.22 · 2022: $225 · 2023: $841 · 2024: $1,662 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,697 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,696.95 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $582.31 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $460.39 | 2023-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $405.64 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $400.29 | 2020-2025 | |
| Lilly USA, LLC | $348.77 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $347.97 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Becton, Dickinson and Company | $225.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.27 | 2023-2025 | Jardiance, Tradjenta, Ofev |
| Exact Sciences Corporation | $142.24 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $136.36 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.97 | 2024-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $102.75 | 2023-2024 | Veozah |
| Merck Sharp & Dohme LLC | $89.88 | 2019-2024 | Gardasil 9, Gardasil, M-M-R II |
| Biogen, INC. | $76.60 | 2025 | Skyclarys |
| Sumitomo Pharma America, INC. | $76.41 | 2024-2025 | Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74.97 | 2019-2025 | Otezla, Repatha, Repatha |
| Phathom Pharmaceuticals, INC. | $74.36 | 2023-2025 | Voquezna |
| Allergan, INC. | $42.03 | 2019-2020 | |
| Mylan Specialty L.P. | $41.63 | 2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $32.19 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $28.39 | 2024 | Inspire |
| Amarin Pharma, INC. | $23.46 | 2019 | |
| Shield Therapeutics INC | $22.63 | 2023 | Accrufer |
| Antares Pharma, INC. | $22.12 | 2024 | Xyosted |
| Corcept Therapeutics | $20.13 | 2024 | Korlym |
| Viatris Specialty LLC | $17.52 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Damle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.